their costs will ramp up with the phase 1 accelerating as well as all the senior management they are bringing on board. They are thinking of possibly opening up another site for the phase 1 trial once they get to the highest dosage… again more money.
the pipeline they want to expand will again cost more money and teams will expand.
I would actually be concerned if they didn’t burn through more cash in the coming quarters, because it would mean they are not running at 100%.
I would be surprised if we don’t raise more capital in mid to late 2022, but by that stage the phase 1 trial will be nearing completion and data from patients with the highest dose may already be available.
And I highly suspect we will be trading much higher than 36.5 cents.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)